CorMedix (CRMD) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
CorMedix (CRMD) PT Lowered to $9 at RBC Capital
March 13, 2024 6:21 AM EDTRBC Capital analyst Gregory Renza lowered the price target on CorMedix (NASDAQ: CRMD) to $9.00 (from $10.00) while maintaining a Outperform rating.
The analyst comments "CRMD reported 4Q, with consistent messaging and incremental updates on launch & reimbursement strategy, into the reaffirmed proposed 4/15 inpatient launch, and... More
